Renal cell carcinoma has been considered a tumor highly insensitive to conventional chemotherapy because of its multivariate biological potential, delayed manifestation of clinical symptoms and the lack of systematic investigation. In this respect, recent advances in pharmacological and pharmaceutical technology promise to be very effectively applied in chemotherapy for this tumor.